ST Pharm Co.,Ltd. (KOSDAQ: 237690)

Market Cap	1.71T
Revenue (ttm)	278.64B
Net Income (ttm)	32.39B
Shares Out	20.13M
EPS (ttm)	1,689.86
PE Ratio	50.18
Forward PE	34.23
Dividend	500.00 (0.59%)
Ex-Dividend Date	Dec 27, 2024

Volume	208,855
Open	86,900
Previous Close	85,100
Day's Range	84,100 - 90,600
52-Week Range	59,900 - 120,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2023, ST Pharm Co.,Ltd.'s revenue was 284.99 billion, an increase of 14.31% compared to the previous year's 249.32 billion. Earnings were 19.58 billion, an increase of 8.78%.